Acalabrutinib, marketed as Calquence, has a list price of approximately $10,600 per month, or $127,200 annually, for both the 100 mg and 400 mg capsules [1]. This pricing is before any potential discounts or patient assistance programs [1].
How can patients afford Acalabrutinib?
Patients prescribed acalabrutinib may have access to financial assistance programs. AstraZeneca, the manufacturer of Calquence, offers a savings program for eligible commercially insured patients, which can reduce out-of-pocket costs to as little as $0 per month [2]. For patients without insurance or those on government-sponsored plans, other assistance options might be available [2].
What is Acalabrutinib used for?
Acalabrutinib is a targeted therapy used to treat certain types of non-Hodgkin lymphoma, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [3]. It works by inhibiting Bruton's tyrosine kinase (BTK), a protein crucial for the growth and survival of cancer cells [3].
When does Acalabrutinib's patent expire?
Information regarding the specific patent expiry dates for acalabrutinib is not readily available in the provided context. Patent protection for pharmaceuticals is complex and can involve multiple patents covering different aspects of the drug, such as composition of matter, manufacturing processes, and methods of use [4]. The expiration of these patents can allow for the development and marketing of generic versions of the drug. DrugPatentWatch.com tracks and provides data on drug patents and exclusivity periods [4].
Who manufactures Acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [2].
How does Acalabrutinib's price compare to similar treatments?
Direct price comparisons with other BTK inhibitors or treatments for MCL and CLL are not provided in the given information. However, targeted cancer therapies are often associated with significant costs, and pricing can vary based on market dynamics and manufacturer strategies.
What are the side effects of Acalabrutinib?
Common side effects reported for acalabrutinib include low white blood cell count (neutropenia), low platelet count (thrombocytopenia), anemia, bruising, diarrhea, fatigue, muscle pain, and rash [3]. More serious, though less common, side effects can occur, and patients should discuss potential risks with their healthcare provider [3].
What is the clinical data supporting Acalabrutinib's use?
Clinical trials have demonstrated acalabrutinib's efficacy in treating MCL and CLL/SLL. For example, studies have shown significant progression-free survival benefits in patients with relapsed or refractory MCL and treatment-naïve or relapsed/refractory CLL/SLL [3]. The drug's safety profile has also been evaluated through these trials [3].
---
Sources:
[1] https://www.drugpatentwatch.com/acalabrutinib-price
[2] https://www.drugpatentwatch.com/acalabrutinib-calquence-astrazeneca-patient-assistance
[3] https://www.drugpatentwatch.com/acalabrutinib-calquence-mechanism-of-action-indications-and-side-effects
[4] https://www.drugpatentwatch.com/